Concepedia
Statistics
Publications
18
Citations
1.4K
H-Index
16
Active since
2013
Affiliations
National Cancer Institute(Current)
Center for Cancer Research
ImmunityBio (United States)
National Institutes of Health
National Institute on Deafness and Other Communication Disorders
Michelle R. Padget is an author at National Cancer Institute specializing in oncology, tumor immunology, and cancer immunology.
Publications per year
2013–2024
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 221 citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochéms, James W. Hodge, Massimo Fantini et al. · Oncotarget · 2016 · 182 citations · Full text
Life Sciences, Immunology, Oncology +16
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
So Jin Park, Wenda Ye, Roy Xiao et al. · Oral Oncology · 2019 · 182 citations · Full text
Medicine, Cancer Biology, Oncology +7
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P. Fabian, Michelle R. Padget, Renee N. Donahue et al. · Journal for ImmunoTherapy of Cancer · 2020 · 149 citations · Full text
Life Sciences, Immunology, Oncology +17
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner et al. · Blood · 2013 · 144 citations · Full text
Medicine, Cancer Biology, Oncology +16
1–5 of 18